Psychedelics & Empathogens in 2026
Psilocybin for AUD. Ibogaine for OUD. MDMA's setback. What the clinical trial landscape actually shows.
Body — 8 lenses: [Science: 5-HT2A agonism (classical psychedelics), MDMA serotonin/dopamine/NE release, ibogaine multi-receptor (anti-addiction window). Biology: acute autonomic effects, serotonin syndrome risk in combos, ibogaine cardiac risk (QT prolongation — real, requires screening), HPPD rare but possible. Psychology: “mystical experience” correlating with therapeutic outcome (Griffiths et al.); challenging experiences and how they’re handled in set/setting. Policy: mostly Schedule I; Oregon Measure 109, Colorado Prop 122, FDA breakthrough designations; MDMA 2024 rejection; state-level initiatives for decrim/regulated access. Trends: psychedelic clinic growth (often off-label ketamine), “microdosing” research (mostly null), ayahuasca tourism. Social: counterculture roots → medicalization → commercialization tension; indigenous reciprocity conversation. Treatment: psilocybin+therapy for AUD (NYU + Hopkins RCTs); ibogaine for OUD (Stanford case series, Kentucky state research); MDMA-AT for PTSD (post-2024 setback, new trials). Harm reduction: set/setting, integration, contraindications (SSRIs, heart conditions, family psychosis history for classical psychedelics), test kits.]
Sources Cited
- 01.Ahttps://heal.nih.govNIH HEAL
- 02.Ahttps://clinicaltrials.govClinicalTrials.gov
- 03.B
Filed Under
sciencebiologypsychologypolicytrendssocial-culturaltreatmentharm-reductionPeer-Reviewed Research
Keep up with the reporting.
One email each morning with the stories that put days like this in context.
Continue reading
More from this section
Psilocybin Lowered Inflammation Markers in Parkinson's Patients. Don't Let Anyone Tell You What That Proves.
A JAMA Psychiatry study reports lower inflammation markers in people with Parkinson's disease after psilocybin. It was small and had no control group. What it can and cannot tell clinicians.
Science & MedicineDoubling the THC Doesn't Double the High. So Why Is Everyone Selling It That Way?
A meta-analysis of 41 THC experiments finds that doubling the dose from 5 to 10 mg raised the self-reported high by about 15 percent and left anxiety unchanged. What it means for people who use, and for providers.
Science & MedicineTwo Postdocs Are Telling the DEA That Schedule I Is Not a Place to Park Uncertainty
Students for Sensible Drug Policy, two early-career scientists and MindState Design Labs asked the DEA for a hearing on placing five tryptamines in Schedule I. What the proposal covers, what it doesn't, and who it could hit first.